U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Showing 1 - 5 of 5 results

Status:
US Approved Rx (2016)
First approved in 1982

Class (Stereo):
CHEMICAL (ABSOLUTE)


Conditions:

Etomidate (AMIDATE®) is an imidazole derivative anesthetic and hypnotic with little effect on blood gases, ventilation, or the cardiovascular system. It is intended for the induction of general anesthesia by intravenous injection. Etomidate (AMIDATE®...
Status:
Other

Class (Stereo):
CHEMICAL (ACHIRAL)


Conditions:

JTC 801 was developed by Japan Tobacco as a novel opioid receptor-like1 (ORL(1)) receptor antagonist. It was found, that JTC-801 completely antagonized the suppression of nociceptin on the forskolin-induced accumulation of cyclic AMP using ORL(1) rec...
Status:
US Approved Rx (2016)
First approved in 1982

Class (Stereo):
CHEMICAL (ABSOLUTE)


Conditions:

Etomidate (AMIDATE®) is an imidazole derivative anesthetic and hypnotic with little effect on blood gases, ventilation, or the cardiovascular system. It is intended for the induction of general anesthesia by intravenous injection. Etomidate (AMIDATE®...
Status:
US Approved Rx (2016)
First approved in 1982

Class (Stereo):
CHEMICAL (ABSOLUTE)


Conditions:

Etomidate (AMIDATE®) is an imidazole derivative anesthetic and hypnotic with little effect on blood gases, ventilation, or the cardiovascular system. It is intended for the induction of general anesthesia by intravenous injection. Etomidate (AMIDATE®...
Status:
Other

Class (Stereo):
CHEMICAL (ACHIRAL)


Conditions:

JTC 801 was developed by Japan Tobacco as a novel opioid receptor-like1 (ORL(1)) receptor antagonist. It was found, that JTC-801 completely antagonized the suppression of nociceptin on the forskolin-induced accumulation of cyclic AMP using ORL(1) rec...